Abstracts Archive - Page 1165 of 2425 - ACR Meeting Abstracts

Abstract Number: 2408 • 2018 ACR/ARHP Annual Meeting
Comparison of the Tear Cytokine and Chemokine Profile of Children with JIA and JIA-Associated Uveitis
Sheila Angeles-Han¹, Virginia Miraldi Utz², Sherry Thornton³, Alyssa Sproles³, Najima Mwase⁴, Theresa Hennard³, Mekibib Altaye⁴ and Gary Holland⁵, ¹Rheumatology, Cincinnati Children's Hospital Medical Center and University of Cincinnati, Cincinnati, OH, ²Pediatric Ophthalmology, Cincinnati Children's Hospital Medical Center and University of Cincinnati, Cincinnati, OH, ³Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Jules Stein Eye Institute, Jules Stein Eye Institute, University of California, Los Angeles, Los Angeles, CA
Background/Purpose: Children with JIA are at increased risk for uveitis. Known risk factors do not accurately stratify risk. Biomarkers are needed to predict uveitis development…
Abstract Number: 2409 • 2018 ACR/ARHP Annual Meeting
Do Children with Juvenile Idiopathic Arthritis Play an Active Role in Their Treatment Adherence? First Results of the Rumaji Study
Guillaume Montagu¹, Ellie Mevel¹, William FAHY², Linda Rossi-Semerano³, Elisabeth Solau-Gervais⁴, Sonia Tropé⁵ and Jean-David Cohen⁶, ¹Research, Unknowns, strategy and innovation consulting, PARIS, France, ²KOURIR, Paris, France, ³Paediatric Rheumatology, Hôpital Kremlin Bicêtre, PARIS, France, ⁴Service de Rhumatologie, CHRU de Poitiers, Poitiers, France, ⁵149 avenue du Maine, ANDAR, Paris, France, ⁶IMMUNO-RHEUMATOLOGY, CHU LAPEYRONIE, MONTPELLIER, France
Background/Purpose: Adherence to DMARDs such as methotrexate and biologics is critical for patients with Juvenile Idiopathic Arthritis (JIA). Notwithstanding, few studies exists on that topic…
Abstract Number: 2410 • 2018 ACR/ARHP Annual Meeting
Determining the Need for Fatigue Management Resources for Young Adults with Rheumatic Disease
Kristine Carandang¹ and Janet L. Poole², ¹Chan Division of Occupational Science & Occupational Therapy, University of Southern California, Los Angeles, CA, ²Health Sciences Ctr OT Program, University of New Mexico, Albuquerque, NM
Background/Purpose: Fatigue is a multi-faceted symptom of rheumatic disease that has high priority among patients due to its far-reaching effects on roles and relationships. There…
Abstract Number: 2411 • 2018 ACR/ARHP Annual Meeting
The Ovarian Reserve Measuring the Anti-Müllerian Hormone Is Not Diminished in Patients with Rheumatoid Arthritis Compared to the Healthy Population
Mireia López-Corbeto¹, Sara Marsal¹, Andrea Pluma², Sergio Martinez², Maria Lopez-Lasanta², Agusti Sellas-Fernandez², Juan José de Agustín² and Mireia Barcelo², ¹Rheumatology Research Group, Vall d'Hebron Hospital Research Institute, Barcelona, Spain, ²Vall d'Hebron Hospital Research Institute, Barcelona, Spain
Background/Purpose: Rheumatoid Arthritis (RA) is the most prevalent chronic inflammatory arthritis, affecting 0.5-1% worldwide population and predominates in females. Altered fertility has been reported due…
Abstract Number: 2412 • 2018 ACR/ARHP Annual Meeting
Evaluating Gaps in Reproductive Health Knowledge Among Women with Rheumatic Diseases
Mehret Birru Talabi¹, Megan E. B. Clowse², Susan J. Blalock³, Lan Yu⁴, Alaina Chodoff⁵ and Sonya Borrero⁴, ¹Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ²Department of Medicine, Division of Rheumatology and Immunology, Duke University, Durham, NC, ³Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁴Medicine, University of Pittsburgh, Pittsburgh, PA, ⁵General Internal Medicine, UPMC, Pittsburgh, PA
Background/Purpose: While women with rheumatic diseases may face considerable reproductive health challenges, few studies have objectively assessed what these women know about their reproductive risks.…
Abstract Number: 2413 • 2018 ACR/ARHP Annual Meeting
Pregnancy Outcomes in Mixed Connective Tissue Disease: Results from a Multicentre Cohort Study
Massimo Radin¹, Karen Schreiber², Maria Jose Cuadrado³, Irene Cecchi⁴, Laura Andreoli⁵, Franco Franceschini⁶, Maria Teresa Caleiro⁷, Danieli Andrade⁸, Elena Gibbone⁹, Munther A Khamashta¹⁰, Jill P. Buyon¹¹, Peter M. Izmirly¹², Maria Aguirre¹³, Chiara Benedetto⁹, Dario Roccatello¹⁴, Luca Marozio¹⁵ and Savino Sciascia¹⁶, ¹Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ²Department of Thrombosis and Haemophilia, Guy's and St Thomas' Hospital, London, United Kingdom., London, United Kingdom, ³Clinica Universidad de Navarra, Madrid, Spain, ⁴Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ⁵Department of Clinical and Experimental Sciences, Spedali Civili and University of Brescia, Brescia, Italy, Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ⁶Department of Clinical and Experimental Sciences, Spedali Civili and University of Brescia, Brescia, Italy, Rheumatology and Clinical Immunology, Brescia, Italy, ⁷Rheumatology, University of São Paulo, Tucson, AZ, ⁸Rheumatology, Hospital das Clinicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ⁹University of Turin, Turin, Italy, ¹⁰Graham Hughes Lupus Research Laboratory, The Rayne Institute, London, United Kingdom, ¹¹Medicine, New York University School of Medicine, New York, NY, ¹²NYU Langone Health, New York, NY, ¹³IMIBIC, Cordoba, Cordoba, Spain, ¹⁴Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bo, Turin, Italy, ¹⁵University of Turin, Torino, Italy, ¹⁶Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Torino, Italy
Background/Purpose: Mixed connective tissue disease (MCTD) is characterized by signs and symptoms of a combination of disorders, primarily systemic lupus erythematosus (SLE), scleroderma and polymyositis…
Abstract Number: 2414 • 2018 ACR/ARHP Annual Meeting
The Global Antiphospholipid Syndrome Score in Women with Systemic Lupus Erythematosus and Adverse Pregnancy Outcomes
Karen Schreiber¹, Massimo Radin², Irene Cecchi³, Elena Rubini⁴, Dario Roccatello⁵, Søren Jacobsen⁶, Maria Jose Cuadrado⁷ and Savino Sciascia⁸, ¹Department of Thrombosis and Haemophilia, Guy's and St Thomas' Hospital, London, United Kingdom., London, United Kingdom, ²Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ³Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ⁴Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bosco Hospital, Turin, Italy., Turin, Italy, ⁵Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bo, Turin, Italy, ⁶University of Copenhagen, Copenhagen, Denmark, ⁷Clinica Universidad de Navarra, Madrid, Spain, ⁸Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Torino, Italy
Background/Purpose: Systemic lupus erythematosus (SLE) and antiphospholipid antibodies (aPL) are associated with pregnancy complications. Methods: 143 women ever pregnant with SLE who presented in our…
Abstract Number: 2415 • 2018 ACR/ARHP Annual Meeting
Increased Sperm DNA Fragmentation in Male Systemic LUPUS Erythematosus Patients
Bruno C Tiseo¹, Clovis A Silva², Eduardo Ferreira Borba³, Gabriela A Munhoz³, Miguel Srougi¹, Eloisa Bonfa⁴ and Marcello Cocuzza¹, ¹Discipline of Urology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil, ²Pediatric Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, Brazil, ³Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, Brazil, ⁴Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Gonadal dysfunction may affect male systemic lupus erythematosus (SLE) patients. Recently, sperm DNA integrity analysis has shown better diagnostic and prognostic performance for predicting…
Abstract Number: 2416 • 2018 ACR/ARHP Annual Meeting
Good Pregnancy and Neonatal Outcomes in Lupus Nephritis Patients with Complete Remission
Weixin HU, Kang LI, Yinghua CHEN, Zhenzhao LIU, Liu YANG, Duqun CHEN and Haitao Zhang, National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China
Background/Purpose: To investigate the outcomes of pregnancy and neonatal and the risk factors of lupus flares and pregnancy complications in Chinese patients with lupus nephritis…
Abstract Number: 2417 • 2018 ACR/ARHP Annual Meeting
Pregnancy Outcomes in Systemic Lupus Erythematous and Pre-Systemic Lupus Erythematous: A Population-Based Cohort Study
A. Nicole Wade¹, Mary A. De Vera², Eric C. Sayre³ and J. Antonio Avina-Zubieta⁴, ¹Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada, ²Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, ³Arthritis Research Canada, Richmond, BC, Canada, ⁴Division of Rheumatology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: The adverse effects of systemic lupus erythematosus (SLE) on maternal and fetal outcomes in pregnancy have been explored mainly in clinic-based cohorts. However, data…
Abstract Number: 2418 • 2018 ACR/ARHP Annual Meeting
Awareness of Fertility and Contraception Issues Among Women with Rheumatologic Diseases
Christina Payne¹, Meagan Clark², Sneha Patel³, Tanya Allawh³, Mei-An Ty-Arias², Ashley Davis² and Arundathi ‎ Jayatilleke ‎⁴, ¹Rheumatology, Drexel University COM/ HUH, Philadelphia, PA, ²Drexel University COM, Philadelphia, PA, ³Internal Medicine, Drexel University COM, Philadelphia, PA, ⁴Rheumatology, Drexel University COM, Philadelphia, PA
Background/Purpose: Because many autoimmune conditions preferentially affect women of childbearing age and both disease and treatment can negatively affect pregnancy outcomes, healthcare providers to women…
Abstract Number: 2419 • 2018 ACR/ARHP Annual Meeting
Needs Assessment and Implementation of a Reproductive Health Intention Screen for Women with Systemic Rheumatic Diseases
Elizabeth Janiak¹, Latoya Bartlett², Joy Gulla², Bill Albert³, Sonali Desai⁴, Susan Ritter⁵, Laura Tarter⁵, Jonathan Coblyn⁵, Bonnie L. Bermas⁶, Wan-Ju Wu¹, Caryn Dutton¹, Lydia Pace⁷ and Candace H. Feldman⁴, ¹Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Power to Decide, Washington, DC, DC, ⁴Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁵Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁶Rheumatology, University of Texas, Southwestern, Dallas, TX, ⁷Division of Women's Health, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Among women with systemic rheumatic diseases (SRD), poor maternal and fetal outcomes may occur if disease activity and medication use are not optimized preconception.…
Abstract Number: 2420 • 2018 ACR/ARHP Annual Meeting
Pregnancy Outcome and Perinatal Complications of Neonate Born to Mothers with Juvenile Idiopathic Arthritis in Asia
Chao-Yi Wu¹, Shang-Chun Changchien², Huang-Yu Yang³, Kuo-Wei Yeh⁴ and Jing-Long Huang^1,2, ¹Division of Allergy, Asthma and Rheumatology. Department of Pediatrics, Chang-Gung Memorial Hospital, Taoyuan city, Taiwan, ²Medicine, Chang-Gung University, Taoyuan city, Taiwan, ³Department of Nephrology,, Chang-Gung Memorial Hospital, Taoyuan city, Taiwan, ⁴Division of Allergy, Asthma and Rheumatology. Department of Pediatrics, Chang-Gung Memorial Hospital, Taoyuan, Taiwan
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the leading pediatric rheumatic disease affecting 30 out of a million women. Although spontaneous remission may occur in most…
Abstract Number: 2421 • 2018 ACR/ARHP Annual Meeting
Pregnancy Outcomes in Women with Rheumatic Diseases and Thrombophilia Treated in a Multidisciplinary Unit
Isabel Añón Oñate¹, Irene Notario¹, Miguel Ángel Ferrer¹, Lorena Pérez¹, María Ramírez¹ and Rafael Cáliz², ¹Rheumatology, Hospital Universitario Virgen de las Nieves, Granada, Spain, ²Hospital Universitario Virgen de las Nieves, Granada, Spain
Background/Purpose: To evaluate the efficacy of the treatment on the pregnancy outcomes of women with Rheumatic Diseases and Thrombophilia from a Spanish cohort. Their pregnancies…
Abstract Number: 2422 • 2018 ACR/ARHP Annual Meeting
Pregnancy Outcomes in Patients with Interstitial Lung Disease Related to Autoimmune Disease and Sarcoidosis
Stephanie L. Giattino, Amanda M. Eudy and Megan E. B. Clowse, Department of Medicine, Division of Rheumatology and Immunology, Duke University, Durham, NC
Background/Purpose: Currently published data regarding pregnancy outcomes in patients with interstitial lung disease (ILD) related to autoimmune disease and sarcoidosis is limited, with widely variant…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].